The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine
The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Signs of an inflammatory process, in particular increased pro-inflammatory cytokines and increased levels of prostaglandine E(2) (PGE(2)), have repeatedly been described in major depression (MD). As cyclooxygenase-2 (COX-2) inhibitors inhibit the PGE(2) production and the production of pro-inflammatory cytokines, we performed a therapeutic trial with the COX-2 inhibitor celecoxib. In a prospective, double-blind, add-on study, 40 patients suffering from an acute depressive episode were randomly assigned to either reboxetine and celecoxib or to reboxetine plus placebo. After a wash-out period, 20 patients received 4-10 mg reboxetine plus placebo and 20 received reboxetine plus 400 mg celecoxib for 6 weeks. The treatment effect was calculated by analysis of variance. There were no significant differences between groups in age, sex, duration or severity of disease or psychopathology, or reboxetine dose or plasma levels. Over 6 weeks, both groups of patients showed significant improvement in scores of the Hamilton Depression Scale. However, the celecoxib group showed significantly greater improvement compared to the reboxetine-alone group. Additional treatment with celecoxib has significant positive effects on the therapeutic action of reboxetine with regard to depressive symptomatology. Moreover, the fact that treatment with an anti-inflammatory drug showed beneficial effects on MD indicates that inflammation is related to the pathomechanism of the disorder, although the exact mechanisms remain to become elucidated.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Patients in the reboxetine plus celecoxib group exhibited reductions in depression severity that were nearly twice as great (55% reduction) as those experienced by patients in the control group (33% reduction).”
From From stress to inflammation and major depressive disorder: A social signal transduction theory of depression. (2014) · cites this paper as Müller et al., 2006
In the citing paper
“75% of patients receiving reboxetine plus celecoxib were categorized as responders, compared to only 45% of patients receiving reboxetine plus placebo”
From From stress to inflammation and major depressive disorder: A social signal transduction theory of depression. (2014) · cites this paper as Müller et al., 2006
In the citing paper
“TNFα antagonists such as etanercept or infliximab and the COX-2 inhibitor celecoxib have all been found to alleviate depressive symptoms in double-blind, randomized, placebo-controlled studies”
From From stress to inflammation and major depressive disorder: A social signal transduction theory of depression. (2014) · cites this paper as Müller et al., 2006
In the citing paper
“One study found positive effects on mood in medically healthy, major depressed patients.52”
From Association of depressive disorders, depression characteristics and antidepressant medication with inflammation (2012) · cites this paper as [52]
In the citing paper
“from the administration of COX2 inhibitors to patients with major depression81”
From From inflammation to sickness and depression: when the immune system subjugates the brain (2008) · cites this paper as [81]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
The global burden of disease, 1990–2020
Lopez, A. D., & Murray, C. C. J. L. (1998) · Nature Medicine · doi:10.1038/3218 · Cited by 1,614
Cytokine-induced sickness behavior: where do we stand?
Dantzer, R. (2001) · Brain, Behavior, and Immunity · doi:10.1006/brbi.2000.0613 · Cited by 862
Cytokine Production and Treatment Response in Major Depressive Disorder
Lanquillon, S. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00134-7 · Cited by 735
Maes, M., Bosmans, E., De Jongh, R., Kenis, G., Vandoolaeghe, E., & Neels, H. (1997) · Cytokine · doi:10.1006/cyto.1997.0238 · Cited by 728
Maes, M., Scharpé, S., Meltzer, H. Y., Bosmans, E., Suy, E., Calabrese, J., & Cosyns, P. (1993) · Psychiatry Research · doi:10.1016/0165-1781(93)90027-e · Cited by 439
Müller, N., Riedel, M., Scheppach, C., Brandstätter, B., Sokullu, S., Krampe, K., Ulmschneider, M., Engel, R. R., Möller, H.-J., & Schwarz, M. J. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.6.1029 · Cited by 388
Self-citationFrommberger, U. H., Bauer, J., Haselbauer, P., Fräulin, A., Riemann, D., & Berger, M. (1997) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/bf02900219 · Cited by 362
Capuron, L., Ravaud, A., Miller, A. H., & Dantzer, R. (2004) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2003.11.004 · Cited by 236
Song, C., Lin, A., Bonaccorso, S., Heide, C., Verkerk, R., Kenis, G., Bosmans, E., Scharpe, S., Whelan, A., Cosyns, P., et al. (1998) · Journal of Affective Disorders · doi:10.1016/s0165-0327(98)00025-1 · Cited by 232
Cited by
Items 601–700 of 802
Repurposing Anti-inflammatory Agents for Mood Disorders: an Updated Review of Current Evidence
Kittur, M. E., Jones, B. D. M., Dai, N., Mahboob, M., & Husain, M. I. (2022) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-022-00267-1 · Cited by 6
Halaris, A. E., Hain, D. T., Law, R., Brown, L., Lewis, D. A., & Filip, M. (2023) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2023.100625 · Cited by 6
Major depressive disorder (mdd): emerging immune targets at preclinical level
Varma, M., Kaur, A., Bhandari, R., Kumar, A., & Kuhad, A. (2023) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2023.2225216 · Cited by 6
Diet, Microbiome, and Neuropsychiatric Disorders
Javitt, G. A., & Javitt, D. C. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811440-7.00013-2 · Cited by 8
Membrane Transporters Contributing to PGE2 Distribution in Central Nervous System
Nakamura, Y., Nakanishi, T., & Tamai, I. (2018) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b18-00169 · Cited by 12
Depression as an Inflammatory Disease
Song, H. R., Sup, W. Y., & Bahk, W. (2013) · 대한정신약물학회지 · Cited by 8
Potential Novel Therapeutics for Bipolar Disorders
Machado‐Vieira, R., Manji, H. K., & Zarate, C. A. (2010) · Current topics in behavioral neurosciences · doi:10.1007/7854_2010_51 · Cited by 6
Causal Network Accounts of Ill-Being: Depression & Digital Well-Being
Byrd, N. (2020) · Philosophical studies series · doi:10.1007/978-3-030-50585-1_11 · Cited by 6
Interleukin-1 beta in psychosocial stress
Yin, W., Godbout, J. P., & Sheridan, J. F. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-817558-3.00007-x · Cited by 9
Qin, Y., Li, J., Chen, F., Wang, L., Bo, T., Zhai, X., & Lu, Y. (2025) · Metabolic Brain Disease · doi:10.1007/s11011-025-01733-4 · Cited by 5
Lessons From Clinical Trials of Immunomodulatory Drugs in Psychiatric Disorders
Pak, T. K., Haque, N., & Jha, M. K. (2025) · Biological Psychiatry · doi:10.1016/j.biopsych.2025.11.009 · Cited by 6
Zhang, K., Ren, H., Ren, X., Wen, P., Xu, K., Liu, L., Xu, P., Zhang, M., Yang, Z., & Yang, M. (2026) · Inflammopharmacology · doi:10.1007/s10787-026-02129-1 · Cited by 5
Anti-Inflammatory Agents as Antidepressants: Truth or Dare
Raison, C. L., & Miller, A. H. (2015) · Psychiatric Annals · doi:10.3928/00485713-20150501-08 · Cited by 5
Pang, C., Yu, H., Xie, J., Chen, Y., Cao, W., Yu, X., Zhu, L., Zhang, J., Gao, L., Li, Y., et al. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.119533 · Cited by 6
Neurological Disorders, Depression and Inflammation: Is there a Common Link?
Halaris, A. E. (2015) · Future Neurology · doi:10.2217/fnl.15.18 · Cited by 6
Depression and inflammation: Pathophysiology and therapeutic implications
Jangpangi, D. (2016) · CHRISMED Journal of Health and Research · doi:10.4103/2348-3334.183728 · Cited by 6
Kronenberg, S. (2011) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.11.47 · Cited by 5
The Inflammatory Hypothesis of Depression
Soskin, D. P., Cassiello-Robbins, C. F., Isacoff, O. K., & Fava, M. (2012) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.10.4.413 · Cited by 5
The role of neuroinflammation in juvenile bipolar disorder
Serra, G., Chiara, L. D., Marangoni, C., & Faedda, G. L. (2015) · Neuroimmunology and Neuroinflammation · doi:10.4103/2347-8659.167303 · Cited by 5
Salehi, A., Rabiei, Z., & Setorki, M. (2020) · Journal of Medicinal Plants · doi:10.29252/jmp.1.73.170 · Cited by 5
Cytokine-Induced Sickness Behavior and Depression
Chang, Q., Szegedi, S. S., O’Connor, J. C., Dantzer, R., & Kelley, K. W. (2008) · Springer eBooks · doi:10.1007/978-0-387-84851-8_9 · Cited by 7
Common Pathways to Neurodegeneration and Co-morbid Depression
Litteljohn, D., Mangano, E. N., & Hayley, S. P. (2010) · Springer eBooks · doi:10.1007/978-90-481-8553-5_8 · Cited by 5
Al‐Hakeim, H. K., Twayej, A. J., Al-Dujaili, A. H., & Maes, M. H. J. (2018) · Preprints.org · doi:10.20944/preprints201812.0131.v1 · Cited by 5
A Forgotten Rose: Embracing the Complexity of Neuroimmune Function
Elkhatib, S. K., Ross, D. A., & Case, A. J. (2021) · Biological Psychiatry · doi:10.1016/j.biopsych.2020.12.020 · Cited by 5
Pawłowski, T., Radkowski, M., Perlejewski, K., Szymańska, B., Berak, H., Horban, A., & Laskus, T. (2025) · PLoS ONE · doi:10.1371/journal.pone.0320221 · Cited by 5
Lolas-Talhami, J., Lafaja-Mazuecos, J., & Ferrández-Sempere, D. (2015) · Open Journal of Obstetrics and Gynecology · doi:10.4236/ojog.2015.56044 · Cited by 4
Vegetarian Diet and Possible Mechanisms for Impact on Mood
Johnston, C. S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-803968-7.00028-9 · Cited by 4
Inflammatory Abnormalities in Major Depressive Disorder
Singhal, G., & Baune, B. T. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-58131-8.00006-9 · Cited by 4
Neuroinflammatory Hypothesis in Major Depressive Disorder
Varma, G. S. (2014) · Psikiyatride Guncel Yaklasimlar - Current Approaches in Psychiatry · doi:10.5455/cap.20130507091423 · Cited by 10
Immunomodulation as Therapeutic Approach in Schizophrenia and Depression: State of the Art
Müller, N. (2015) · Current topics in neurotoxicity · doi:10.1007/978-3-319-13602-8_17 · Cited by 5
Self-citationMaxeiner, H. G., Rojewski, M., Tumani, H., Herzog, S., Fuchs, D., Schmitt, A., Schmitt, M. W., & Bechter, K. (2009) · Acta Neuropsychiatrica · doi:10.1017/s0924270800032737 · Cited by 4
Curcumin as an ajuvant treatment of depression: mechanisms of action and application prospects
Ab, K. (2020) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro2020120021125 · Cited by 4
Radkowski, M., Kryczka, T., Szymańska, B., Berak, H., Horban, A., Pawłowski, T., Perlejewski, K., & Laskus, T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242015351 · Cited by 6
Neurochemical and Transmitter Models of Depression
Anisman, H., Matheson, K., & Hayley, S. P. (2008) · Elsevier eBooks · doi:10.1016/b978-0-08-045078-0.00004-6 · Cited by 7
The Microbiome–Gut–Brain Axis and the Consequences of Infection and Dysbiosis
Bienenstock, J., Kunze, W., & Forsythe, P. (2016) · The American Journal of Gastroenterology Supplements · doi:10.1038/ajgsup.2016.12 · Cited by 5
Treatment resistant depression: Challenges and therapeutic choices
Touloumis, C. (2021) · Psychiatriki · doi:10.22365/jpsych.2021.047 · Cited by 4
Vrousgos, G. (2016) · Open Medicine Journal · doi:10.2174/1874220301603010034 · Cited by 4
Immunoinflammatory Therapies in Psychiatry: Current Evidence Base
Menon, V., & Ameen, S. (2017) · Indian Journal of Psychological Medicine · doi:10.4103/ijpsym.ijpsym_505_17 · Cited by 5
Akóṣílè, W. (2021) · Queensland University of Technology · doi:10.5204/thesis.eprints.210971 · Cited by 4
Inflammatory models of depression in rodents and humans
Markov, D., Zozulya, S. A., & Dolotov, O. V. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1687579 · Cited by 5
Los efectos conductuales modulados por las citocinas
Becerril‐Villanueva, E., Gutiérrez, M. E. H., Granados-Camacho, I., Alvarez, L., Pérez‐Tapia, S. M., & Romero, L. P. (2012) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) · Cited by 5
TECHNOLOGY OF IMMUNOCORRECTION AT MENTAL DISORDERS
Vetlugina, T. P., Невидимова, Т. И., Лобачева, О. А., & Nikitin, V. B. (2010) · doi:10.17513/np.103 · Cited by 4
Clinical Trials of Anti-Inflammatory Treatments of Major Depression
Müller, N. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811073-7.00028-3 · Cited by 3
Self-citationKraneveld, A. D., & Garssen, J. (2014) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-319-06151-1_22 · Cited by 3
Efficacy of Anti-Inflammatory Treatment in Depression
Köhler‐Forsberg, O., & Benros, M. E. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811073-7.00030-1 · Cited by 4
Neurobiological Principles: Psycho-Neuro-Immuno-Endocrinology
Müller, N. (2020) · Springer eBooks · doi:10.1007/978-3-319-56015-1_2-1 · Cited by 3
Self-citationMurata, S., Murphy, M. L. M., Khanna, R., Hoppensteadt, D., Fareed, J., & Halaris, A. E. (2021) · Journal of Affective Disorders Reports · doi:10.1016/j.jadr.2021.100117 · Cited by 3
Modulating Neuroplasticity: Lessons Learned from Antidepressants and Emerging Novel Therapeutics
Yates, C. G., Kruse, J. L., Price, J. B., Robertson, A. A. B., & Tye, S. J. (2021) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-021-00249-9 · Cited by 4
Traditional and Novel Possible Targets for Antidepressant Drugs
Palazidou, E. (2016) · Springer eBooks · doi:10.1007/978-3-319-14021-6_2 · Cited by 5
Stress, Inflammation and Neurogenesis in Major Depression
Kim, Y. K. (2011) · Cited by 3
Anti-Inflammatory and Immune-Modulatory Therapeutic Approaches in Major Depression
Müller, N. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802456-0.00004-2 · Cited by 4
Self-citationFuture Drugs for the Treatment of Depression: The Need to Look Beyond Monoamine Systems
Rapaport, M. H. (2009) · CNS Spectrums · doi:10.1017/s109285290000359x · Cited by 3
Diagnosis of Major Depressive Disorders: Clinical and Biological Perspectives
Fakhoury, M. (2017) · Springer eBooks · doi:10.1007/978-981-10-6577-4_4 · Cited by 5
Major Depression: An Immune-Inflammatory Disorder
Noto, C. D. S., Rizzo, L. B., Mansur, R. B., Brietzke, E. M., & Maes, M. H. J. (2015) · Current topics in neurotoxicity · doi:10.1007/978-3-319-13602-8_8 · Cited by 4
Steyn, S. F. (2011) · Boloka Institutional Repository (North-west University) · Cited by 5
Tanaka, K., & Furuyashiki, T. (2012) · Folia Pharmacologica Japonica · doi:10.1254/fpj.139.152 · Cited by 2
Stern, L., Agam, G., Shvartsur, R., Alhoashla, A., Tailakh, M. A., & Azab, A. N. (2026) · Pharmaceuticals · doi:10.3390/ph19030435 · Cited by 2
Immunomodulation of Resistant Depression
Bennabi, D., & Haffen, É. (2021) · Springer eBooks · doi:10.1007/978-3-030-71229-7_23 · Cited by 2
Hennessy, M. B., Miller, J. A., Carter, K. A., Molina, A. L., Schiml, P. A., & Deak, T. (2022) · Developmental Psychobiology · doi:10.1002/dev.22237 · Cited by 3
Kundu Smita, S., & Rana, D. G. (2022) · Research Journal of Pharmacy and Technology · doi:10.52711/0974-360x.2022.00344 · Cited by 2
Immune cell markers associated with early life major depressive episodes
Roberson‐Nay, R., Lapato, D. M., Gentry, A. E., Lancaster, E. E., & York, T. P. (2024) · Journal of Mood and Anxiety Disorders · doi:10.1016/j.xjmad.2024.100049 · Cited by 2
de Araújo, M. R., Haddad, M., Dieckmann, L. H. J., & Mari, J. D. J. (2025) · Springer eBooks · doi:10.1007/978-3-031-81802-8_1 · Cited by 4
A computational account of joint SSRI and anti-inflammatory treatment
Reneaux, M., Mayberg, H. S., Friston, K. J., & Pinotsis, D. A. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1472732 · Cited by 6
Underlying biological substrates associated with cognitive dysfunction in major depressive disorder
(2015) · Cambridge University Press eBooks · doi:10.1017/cbo9781139860567.012 · Cited by 2
Strategies to Identify Biomarkers for Depression
Páez-Pereda, M., & Panhuysen, M. (2008) · Springer eBooks · doi:10.1007/978-0-387-79251-4_13 · Cited by 3
Antipsychotic-like effect of agomelatine in a rodent model
Erbaş, O., Eliküçük, B., Solmaz, V., & Akseki, H. S. (2015) · Dusunen Adam The Journal of Psychiatry and Neurological Sciences · doi:10.5350/dajpn2015280206 · Cited by 2
It all happens between Toll receptors and Caspase 1
Sánchez-Alavez, M., & Bartfai, T. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702505104 · Cited by 2
Hassanin, H. (2015) · Egyptian Journal of Geriatrics and Gerontology · doi:10.21608/ejgg.2015.5323 · Cited by 3
Improvement of late life depression after therapeutic enoxaparin: two case reports
Graham, D., Wu, Q. X., Gilligan, I., Ismail, R., & Walker, M. (2018) · Australasian Psychiatry · doi:10.1177/1039856218797441 · Cited by 2
Иванова, Е. А., Matyushkin, A. I., Васильчук, А. Г., & Воронина, Т. А. (2021) · Moscow University Biological Sciences Bulletin · doi:10.3103/s009639252103007x · Cited by 3
Biological Models of Unipolar Depression
Cleare, A. J., & Rane, L. J. (2013) · Wiley eBooks · doi:10.1002/9781118316153.ch2 · Cited by 5
Inflammation-induced depression : Studying the role of proinflammatory cytokines in anhedonia
van Heesch, F. (2014) · Utrecht University Repository (Utrecht University) · Cited by 13
Himmerich, H. (2008) · Springer eBooks · doi:10.1007/978-3-540-68748-1_16 · Cited by 2
Modern Trends of Pharmacotherapy in PsychoNeuroImmunology
Sarvilina, I. V. (2024) · Integrated science · doi:10.1007/978-3-031-73061-0_24 · Cited by 2
Hennessy, M. B., Slomski, O., Spenny, J. L., Sharma, T. R., Schiml, P. A., & Deak, T. (2025) · Developmental Psychobiology · doi:10.1002/dev.70033 · Cited by 1
Post-traumatic Stress Disorder (PTSD): Linking Inflammatory and Neural Factors
Mudgal, J., Govindula, A., & Arora, D. S. (2024) · Springer eBooks · doi:10.1007/978-3-031-32035-4_86-1 · Cited by 1
Palladini, M., Azzalin, A. A., Bessi, M., LORENZO, R. D., Rovere, P. Q., Benedetti, F., & Mazza, M. G. (2025) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-025-10247-w · Cited by 1
Response to immune-based augmentation treatment for depression: a potential role of immunosenescence
Assche, E. V., Hohoff, C., Wissing, S. M., Steinbach, L., & Baune, B. T. (2026) · Neuroscience Applied · doi:10.1016/j.nsa.2026.106986 · Cited by 1
Neuroimaging and Clinical Studies on Brain–Immune Interactions
Hannestad, J. O. (2012) · Springer eBooks · doi:10.1007/978-1-4614-4729-0_4 · Cited by 1
Use of Adjunctive Therapy in Older Depressed Adults Who are Resistant to Antidepressant Treatment
Nelson, J. C. (2013) · Oxford University Press eBooks · doi:10.1093/med/9780199796816.003.0021 · Cited by 1
Immunopathology of the Nervous System
Remick, A. K., Pershing, M. L., Papenfuss, T. L., Lanigan, L. G., Beck, M. J., & Toot, J. (2017) · Molecular and integrative toxicology · doi:10.1007/978-3-319-47385-7_5 · Cited by 1
Kundu Smita, S., & Rana, D. G. (2021) · Asian Journal of Pharmaceutical and Clinical Research · doi:10.22159/ajpcr.2021.v14i7.41249 · Cited by 1
Interaction Between Inflammatory State and Neurochemical Changes in Major Psychiatric Disorders
Mu, A., & Markus, J. (2011) · InTech eBooks · doi:10.5772/25532 · Cited by 1
Novel Therapeutic Approaches for Treating Bipolar Disorder
Machado‐Vieira, R., Henter, I. D., Baumann, J., Latov, D. R., Wheeler‐Castillo, C., & Zarate, C. A. (2011) · Wiley eBooks · doi:10.1002/9780470975114.ch21 · Cited by 1
Sidorova, Y. V., Obraztsova, O. G., Евдокимов, Д. В., Абрамец, И. И., & Talalayenko, A. N. (2013) · Neurophysiology · doi:10.1007/s11062-013-9357-6 · Cited by 1
The interface between neurology and psychiatry: the case of multiple sclerosis
Wong, E., Krishnadas, R., & Cavanagh, J. (2013) · Advances in Psychiatric Treatment · doi:10.1192/apt.bp.112.010710 · Cited by 1
Inflammation in depression: the role of cytokines
Gümrü, S., & Arıcıoğlu, F. (2012) · Clinical and Experimental Health Sciences · Cited by 6
Biomarker in der Depressionsbehandlung: mehr als nur Worte?
Bosch, O. G., & Breitenstein, B. (2015) · Zeitschrift für Psychiatrie Psychologie und Psychotherapie · doi:10.1024/1661-4747/a000244 · Cited by 3
Segărceanu, A., Prada, G. I., Ionescu, C., Arsene, A. L., Fulga, I., & Davila, C. (2012) · Cited by 2
Neurogenesis, Inflammation, and Mental Health
Borsini, A., Sawyer, K. M., Zunszain, P. A., & Pariante, C. M. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811073-7.00006-4 · Cited by 3
Depression and Cardiovascular Risk: Epidemiology, Mechanisms, and Implications
Hatch, J. K., & Goldstein, B. I. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813333-0.00017-2 · Cited by 1
The use of cyclooxygenase-2 inhibitors in depression: a narrative review of the state of evidence
Abbas, A., Kumar, N., & Choudhary, R. (2019) · International Journal of Basic & Clinical Pharmacology · doi:10.18203/2319-2003.ijbcp20194286 · Cited by 1
Varney, A., Womersley, K., & Agius, M. (2017) · PubMed · Cited by 3
Präklinische Einblicke in das Zusammenspiel von Mikrobiota und Verhalten
Schmidtner, A. K., & Neumann, I. D. (2020) · Nervenheilkunde · doi:10.1055/a-1036-4206 · Cited by 1
Immunotherapies for Depression
Kappelmann, N., Bullmore, E. T., & Khandaker, G. M. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108539623.009 · Cited by 1
Inflammatory Biomarkers and Depression
Müller, N., Myint, A.-M., & Schwarz, M. (2013) · Springer eBooks · doi:10.1007/978-1-4614-7264-3_8 · Cited by 1
Self-citationHimmerich, H., & Schneider, F. W. (2016) · Springer eBooks · doi:10.1007/978-3-662-50345-4_39 · Cited by 1
Depression and Cancer: The Inflammatory Bridge
Leite, F., & Leite, Â. M. T. (2023) · Interdisciplinary cancer research · doi:10.1007/16833_2022_106 · Cited by 1
Trongtorsak, P. (2018) · Chulalongkorn Medical Journal · doi:10.58837/chula.cmj.62.4.2 · Cited by 2
The Role of Immunotherapy in the Treatment of Major Depressive Disorder A Narrative Review
Soares, F. R., Buinho, A., de Oliveira, T. M., de Sá, Z. C., Rema, J., & Novais, F. (2025) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-025-00355-y · Cited by 2
Metadata
- Authors
- Müller, N., Schwarz, M. J., Dehning, S., Douhe, A., Cerovecki, A., Goldstein-Müller, B., Spellmann, I., Hetzel, G., Maino, K., Kleindienst, N., Möller, H.-J., Arolt, V, & Riedel, M.
- Affiliations
- Ludwig-Maximilians-Universität München (DE)
- University of Münster (DE)
- Corresponding author
- Müller, N
- Venue
- Molecular Psychiatry
- Published
- 2006-02-21
- Volume
- 11
- Issue
- 7
- Pages
- 680-684
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- OpenAlex
- W2049808835
- Cited by
- 794
- References
- 37
- Citations by year
- 2026: 10 · 2025: 20 · 2024: 24 · 2023: 30 · 2022: 42 · 2021: 42 · 2020: 37 · 2019: 44 · 2018: 52 · 2017: 45 · 2016: 42 · 2015: 54 · 2014: 53 · 2013: 61 · 2012: 50
- FWCI
- 20.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Molecular Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Keywords
- celecoxib, COX-2 inhibitors, major depressive disorder, reboxetine, anti-inflammatory therapy, inflammatory cytokines, prostaglandin E2, adjunctive therapy, acute depressive episode
- MeSH terms
- Celecoxib, Reboxetine, Adult, Antidepressive Agents, Depressive Disorder, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Inflammation, Lorazepam, Male, Middle Aged, Morpholines, Patient Dropouts, Pilot Projects, Psychological Tests, Pyrazoles, Serotonin, Severity of Illness Index, Sulfonamides, Anti-Anxiety Agents, Dinoprostone, Interleukin-6, Adrenergic Uptake Inhibitors, Cyclooxygenase 2 Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.